Pharmacotherapy of heart failure with preserved ejection fraction.

摘要: Heart failure with preserved ejection fraction (HFpEF) constitutes ~50% of all heart diagnoses and is associated considerable morbidity mortality. The treatment HFpEF can be challenging due to a lack evidence supporting the benefit various drug therapies. In practice, divided into acute chronic management. Acute therapy for decompensated similar both reduced fraction. mainstay diuretics reduce volume overload improve dyspnea. Patients an exacerbation rapid atrial fibrillation (AF) should rate controlled negative chronotropic agents. For therapy, patients not treated like Chronic management simplified by using three strategies based on applicability: treat precipitating conditions (e.g., hypertension, AF), control symptoms maintaining euvolemia diuretics, avoid therapies that have been shown beneficial unless another compelling indication exists. Nondrug interventions include salt fluid restriction, regular physical activity, referral function clinic, if appropriate.